Valuation : ImmuPharma plc

Market Cap 21.84M 29.61M 25.51M 23.92M 41.14M 2.83B 41.27M 284M 111M 1.43B 111M 109M 4.74B P/E 2024
-2.01x
P/E 2025 -16.8x
Enterprise Value 20.48M 27.78M 23.93M 22.44M 38.59M 2.65B 38.71M 266M 104M 1.34B 104M 102M 4.44B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
95.03%
Yield 2024 *
-
Yield 2025 -
1 week-12.28%
Current month-2.23%
1 month-22.22%
3 months-18.60%
6 months-56.41%
Current year-43.55%
1 week 3.4
Extreme 3.4
4.15
1 month 3.3
Extreme 3.3
4.45
Current year 3.3
Extreme 3.3
11
1 year 2.25
Extreme 2.253
19.4
3 years 0.82
Extreme 0.822
19.4
5 years 0.82
Extreme 0.822
19.4
10 years 0.82
Extreme 0.822
193.74
Manager TitleAgeSince
Chief Executive Officer 70 29/07/2021
Director of Finance/CFO - 02/12/2024
Chief Tech/Sci/R&D Officer - 31/08/2025
Director TitleAgeSince
Director/Board Member 60 28/07/2021
Chairman 70 29/09/2015
Director/Board Member 62 15/07/2021
Date Insider Type Main position Quantity % Market Cap.
19/04/24 Free

Director

3,000,000 0.7204%
19/04/24 Free

Director

2,000,000 0.4803%
22/12/22 Free

Chief Executive Officer

1,800,000 0.5399%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-12.28%+57.30%+41.13% 29.61M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.38%-2.18%+77.85%+103.31% 27.46B
Weighted average by Cap. -1.70%-1.06%+96.27%+129.02%

Financials

2024 2025
Net sales - -
Net income -2.48M -3.37M -2.9M -2.72M -4.68M -322M -4.69M -32.28M -12.59M -162M -12.64M -12.37M -539M -1.81M -2.45M -2.11M -1.98M -3.41M -234M -3.42M -23.49M -9.17M -118M -9.2M -9M -392M
Net Debt -237K -321K -277K -260K -446K -30.7M -448K -3.08M -1.2M -15.5M -1.21M -1.18M -51.39M -1.35M -1.83M -1.58M -1.48M -2.55M -175M -2.56M -17.57M -6.86M -88.46M -6.88M -6.73M -293M
Logo ImmuPharma plc
ImmuPharma PLC is a specialist drug discovery and development company. The Company is engaged in the development of drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases with high medical need. Its lead program, P140, is a non-immunosuppressing, convenient and safe peptide treatment for autoimmune disease, which is in late-stage development for the treatment of systemic lupus erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB is an advanced anti-infective candidate. It is an improved form of amphotericin-B (AMB), a systemic antifungal drug. BioCin is an improved form of vancomycin, a systemic antibacterial which is highly effective against Methicillin-resistant Staphylococcus Aureus (MRSA) and orally against Clostridium Difficile infections.
Employees
7
Date Price Change Volume
28/08/26 GBX 3.500 0.00% 2,391,530
27/08/26 GBX 3.500 -6.54% 2,412,650
26/08/26 GBX 3.745 +9.82% 879,758
25/08/26 GBX 3.410 +0.15% 1,929,507
24/08/26 GBX 3.405 -14.66% 1,369,071